PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.

Abstract Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (1:1, Δ-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects.
PMID
Related Publications

Psychosocial interventions for cannabis use disorder.

Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors

Mayor MeshTerms

Outcome Assessment (Health Care)

Keywords
Journal Title journal of addiction medicine
Publication Year Start




PMID- 27261670
OWN - NLM
STAT- MEDLINE
DCOM- 20170412
LR  - 20171116
IS  - 1935-3227 (Electronic)
IS  - 1932-0620 (Linking)
VI  - 10
IP  - 4
DP  - 2016 Jul-Aug
TI  - Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for
      Cannabis Dependence: A Case Series.
PG  - 274-9
LID - 10.1097/ADM.0000000000000229 [doi]
AB  - OBJECTIVES: Cannabis is the most commonly used illicit drug; a substantial
      minority of users develop dependence. The current lack of pharmacological
      treatments for cannabis dependence warrants the use of novel approaches and
      further investigation of promising pharmacotherapy. In this case series, we
      assessed the use of self-titrated dosages of Sativex (1:1,
      Delta-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational 
      enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment 
      of cannabis dependence among 5 treatment-seeking community-recruited
      cannabis-dependent subjects. METHODS: Participants underwent a 3-month open-label
      self-titration phase with Sativex (up to 113.4 of THC/105 mg of CBD) and weekly
      MET/CBT, with a 3-month follow-up. RESULTS: Sativex was well-tolerated by all
      participants (average dosage 77.5 THC/71.7 mg CBD). The combination of Sativex
      and MET/CBT reduced the amount of cannabis use and progressively reduced craving 
      and withdrawal scores. THC/CBD metabolite concentration indicated reduced
      cannabis use and compliance with medication. CONCLUSIONS: In summary, this pilot 
      study found that with Sativex in combination with MET/CBT reduced cannabis use
      while preventing increases in craving and withdrawal in the 4 participants
      completing the study. Further systematic exploration of Sativex as a
      pharmacological treatment option for cannabis dependence should be performed.
FAU - Trigo, Jose M
AU  - Trigo JM
AD  - Translational Addiction Research Laboratory, Campbell Family Mental Health,
      Research Institute (JMT, AS, GS, BLF); Clinical Research (LQ); Social and
      Epidemiological Research Department (BF, JR); Schizophrenia Division and Complex 
      Mental Illness Program, Centre for Addiction and Mental Health (CAMH), Toronto,
      Canada (TPG); Addiction Policy, Dalla Lana School of Public Health (JR);
      Institute of Medical Science, University of Toronto, Faculty of Medicine (BF,
      JR); Department of Psychiatry, University of Toronto, Toronto, Canada (BF, TPG,
      JR, PS); Institute of Clinical Psychology and Psychotherapy & Center of Clinical 
      Epidemiology and Longitudinal Studies (CELOS), Technische Universitat Dresden,
      Dresden, Germany (JR); Addictions Division, CAMH (PS, BLF); Department of Family 
      and Community Medicine, University of Toronto, Toronto (PS); Centre for Applied
      Research in Mental Health & Addiction, Faculty of Health Sciences, Simon Fraser
      University, Vancouver, Canada (BF); and Chemistry and Drug Metabolism, National
      Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore,
      MD (AJB, MAH).
FAU - Soliman, Alexandra
AU  - Soliman A
FAU - Staios, Gregory
AU  - Staios G
FAU - Quilty, Lena
AU  - Quilty L
FAU - Fischer, Benedikt
AU  - Fischer B
FAU - George, Tony P
AU  - George TP
FAU - Rehm, Jurgen
AU  - Rehm J
FAU - Selby, Peter
AU  - Selby P
FAU - Barnes, Allan J
AU  - Barnes AJ
FAU - Huestis, Marilyn A
AU  - Huestis MA
FAU - Le Foll, Bernard
AU  - Le Foll B
LA  - eng
GR  - R21 DA031906/DA/NIDA NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - J Addict Med
JT  - Journal of addiction medicine
JID - 101306759
RN  - 0 (Drug Combinations)
RN  - 0 (Plant Extracts)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
RN  - K4H93P747O (nabiximols)
SB  - IM
MH  - Adult
MH  - Cannabidiol
MH  - Cognitive Therapy/*methods
MH  - Combined Modality Therapy
MH  - Dronabinol
MH  - Drug Combinations
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Marijuana Abuse/*drug therapy
MH  - Middle Aged
MH  - Motivational Interviewing/*methods
MH  - *Outcome Assessment (Health Care)
MH  - Pilot Projects
MH  - Plant Extracts/administration & dosage/*pharmacology
MH  - Recurrence
MH  - Secondary Prevention/*methods
PMC - PMC5586546
MID - NIHMS782634
EDAT- 2016/06/05 06:00
MHDA- 2017/04/13 06:00
CRDT- 2016/06/05 06:00
PHST- 2016/06/05 06:00 [entrez]
PHST- 2016/06/05 06:00 [pubmed]
PHST- 2017/04/13 06:00 [medline]
AID - 10.1097/ADM.0000000000000229 [doi]
PST - ppublish
SO  - J Addict Med. 2016 Jul-Aug;10(4):274-9. doi: 10.1097/ADM.0000000000000229.